Ray Dalio's RPRX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 219,687 shares of Royalty Pharma plc (RPRX) worth $12.32 M, representing 0.05% of the portfolio. First purchased in 2020-Q4, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in RPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 350,314 shares. Largest reduction occurred in Q3 2024, reducing 238,991 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Royalty Pharma plc (RPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Royalty Pharma plc (RPRX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +219,687 | New Buy | 219,687 | $56.07 |
| Q1 2025 | -49,416 | Sold Out | 0 | $0.00 |
| Q4 2024 | +49,416 | New Buy | 49,416 | $25.51 |
| Q3 2024 | -238,991 | Sold Out | 0 | $0.00 |
| Q2 2024 | -132,471 | Reduce 35.66% | 238,991 | $26.37 |
| Q1 2024 | +350,314 | Add 1656.49% | 371,462 | $30.37 |
| Q4 2023 | -172,028 | Reduce 89.05% | 21,148 | $28.09 |
| Q3 2023 | +80,538 | Add 71.50% | 193,176 | $27.14 |
| Q2 2023 | +79,201 | Add 236.87% | 112,638 | $30.74 |
| Q1 2023 | -5,656 | Reduce 14.47% | 33,437 | $36.03 |
| Q4 2022 | -22,759 | Reduce 36.80% | 39,093 | $39.52 |
| Q3 2022 | +56,543 | Add 1065.04% | 61,852 | $40.18 |
| Q2 2022 | -35,178 | Reduce 86.89% | 5,309 | $42.00 |
| Q1 2022 | +34,739 | Add 604.37% | 40,487 | $38.95 |
| Q4 2021 | +5,748 | New Buy | 5,748 | $39.84 |
| Q3 2021 | -18,347 | Sold Out | 0 | $0.00 |
| Q2 2021 | +18,347 | New Buy | 18,347 | $40.99 |
| Q1 2021 | -13,535 | Sold Out | 0 | $0.00 |
| Q4 2020 | +13,535 | New Buy | 13,535 | $50.02 |
Ray Dalio's Royalty Pharma plc Investment FAQs
Ray Dalio first purchased Royalty Pharma plc (RPRX) in Q4 2020, acquiring 13,535 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Royalty Pharma plc (RPRX) for 19 quarters since Q4 2020.
Ray Dalio's largest addition to Royalty Pharma plc (RPRX) was in Q1 2024, adding 371,462 shares worth $11.28 M.
According to the latest 13F filing for Q2 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 219,687 shares of Royalty Pharma plc (RPRX), valued at approximately $12.32 M.
As of the Q2 2026 filing, Royalty Pharma plc (RPRX) represents approximately 0.05% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Royalty Pharma plc (RPRX) was 371,462 shares, as reported at the end of Q1 2024.